

August 19, 2020

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides announces successful completion of UK MHRA inspection at Puducherry facility”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,



**Manjula Ramamurthy**  
Company Secretary



Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

**Corp Off:** Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India  
Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

**Regd Off:** 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India  
Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

---

## **Strides announces successful completion of UK MHRA inspection at Puducherry facility**

### ***Continued GMP status for the facility from UK MHRA***

---

**Bengaluru, August 19, 2020** – Strides Pharma Science Limited (Strides) today announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) at its Puducherry facility between 15-18 October 2019. The Company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection. The Puducherry facility caters to the U.S., Other Regulated Markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats.

Commenting on the development, **Dr. R. Ananthanarayanan, Managing Director & CEO**, remarked *“We are pleased with the positive outcome of the inspection by the UK MHRA at our Puducherry facility. The inspection was conducted a few months after the USFDA inspection that resulted in the Warning Letter. We stay focused on getting the facility reclassified with the USFDA. We are committed to upholding the highest levels of quality compliance and integrity across all our manufacturing sites”*

#### **About Strides**

Strides, listed on the BSE (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at [www.strides.com](http://www.strides.com)

#### **For further information, please contact:**

##### **Strides**

**Badree Komandur**

Executive Director – Finance & Group CFO  
+91 80 6784 0747

##### **Investor Relations**

**Sandeep Baid:** +91 80 6784 0791  
Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

##### **Corporate Communication**

**Usha Iyer:** +91 9987444106  
Email: [usha.iyer@strides.com](mailto:usha.iyer@strides.com)

##### **PR Consultancy**

Fortuna PR  
**K Srinivas Reddy:** +91 90005 27213  
[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,  
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta  
Road, Bengaluru – 560 076

K Priya: +91 95354 25418

[priya@fortunapr.com](mailto:priya@fortunapr.com)